Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb.
By A. Izzo, F. Borrelli, R. Capasso, V. Di Marzo, R. Mechoulam. TIPS - Trends in Pharmacological Sciences, 2009
791 citations recorded by the source corpus.
Subfields: Cognitive Neuroscience, Pharmacology, Plant Science
View Paper: https://www.semanticscholar.org/paper/15c6a03461ce80ef39587bf86e8b88d4b20457a2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cognitive Neuroscience
In Pharmacology
In Plant Science
Citations in the corpus
- Cannabidiol as a Potential Treatment for Anxiety Disorders (2015, background): “CBD has a broad pharmacological profile, including interactions with several receptors known to regulate fear and anxiety-related behaviors, specifically the cannabinoid type 1 receptor (CB1R), the serotonin 5-HT1A receptor, and the transient receptor potential (TRP) vanilloid type 1 (TRPV1) recepto”
- Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes (2011, background): “In conclusion, our data support the current concept (Izzo et al., 2009) that not only cannabinoids different from British Journal of Pharmacology (2011) 163 1479–1494 1491 THC (and CBD), but also cannabis extracts enriched in such compounds, might be used in the future as potential therapeutic…”
- Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System (2018, background): “Due to the clinical application of marijuana and the non-psychoactive nature of most phytocannabinoids except THC, the therapeutic potential of these compounds has been greatly appreciated [14].”